The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Long-term effects of psychedelic drugs: A systematic review
Abstract
Research into the basic effects and therapeutic applications of psychedelic drugs has grown considerably in recent years. Yet, pressing questions remain regarding the substances' lasting effects. Although individual studies have begun monitoring sustained changes, no study to-date has synthesized this information. Therefore, this systematic review aims to fill this important gap in the literature by synthesizing results from 34 contemporary experimental studies which included classic psychedelics, human subjects, and follow-up latencies of at least two weeks. The bulk of this work was published in the last five years, with psilocybin being the most frequently administered drug. Enduring changes in personality/attitudes, depression, spirituality, anxiety, wellbeing, substance misuse, meditative practices, and mindfulness were documented. Mystical experiences, connectedness, emotional breakthrough, and increased neural entropy were related to these long-term changes in psychological functioning. Finally, with proper screening, preparation, supervision, and integration, limited aversive side effects were noted by study participants. Future researchers should focus on including larger and more diverse samples, lengthier longitudinal designs, stronger control conditions, and standardized dosages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Brunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413
Psychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. J. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 312
Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817706884 · Cited by 311
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 302
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
The hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 267
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1824-6 · Cited by 265
Psychedelics and connectedness
Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4701-y · Cited by 265
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248
Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214377 · Cited by 247
Self-citationPsychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
Psychedelic Drugs Reconsidered
Grinspoon, L., & Bakalar, J. B. (1979) · Medical Entomology and Zoology · Cited by 239
Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.103309 · Cited by 237
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230
George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.015 · Cited by 230
Hartogsohn, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00129 · Cited by 229
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citationBouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
LSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 201
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Forstmann, M., & Sagioglou, C. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117714049 · Cited by 196
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183
Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 182
Anxiety and depression in Nepal: prevalence, comorbidity and associations
Risal, A., Manandhar, K., Linde, M., Steiner, T. J., & Holen, A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0810-0 · Cited by 182
Lyons, T., & Carhart-Harris, R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117748902 · Cited by 178
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172
Emotions and Affect in Human Factors and Human-Computer Interaction
Jeon, M. (2017) · Cited by 143
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142
Self-citationDavis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140
Self-citationSerotonergic Hallucinogen-Induced Visual Perceptual Alterations
Kometer, M., & Vollenweider, F. X. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_461 · Cited by 137
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00100 · Cited by 134
Halpern, J. H., Lerner, A. G., & Passie, T. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_457 · Cited by 133
Stroud, J., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D. J., Curran, H. V., & Carhart-Harris, R. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4754-y · Cited by 126
Flashbacks: Recurrent Intrusive Images After the Use of LSD
Horowitz, M. J. (1969) · American Journal of Psychiatry · doi:10.1176/ajp.126.4.565 · Cited by 125
Long Lasting Effects of LSD on Normals
McGlothlin, W. H. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730290009002 · Cited by 119
Barbosa, P. C. R., Cazorla, I. M., Giglio, J. S., & Strassman, R. J. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10400530 · Cited by 118
Behavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 118
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513851 · Cited by 103
Psychedelics and music: neuroscience and therapeutic implications
Barrett, F. S., Preller, K. H., & Kaelen, M. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1484342 · Cited by 103
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970
Dyck, E. (2006) · Social History of Medicine · doi:10.1093/shm/hkl039 · Cited by 102
The association of psychedelic use and opioid use disorders among illicit users in the United States
Pisano, V. D., Putnam, N. P., Kramer, H. M., Franciotti, K., Halpern, J. H., & Holden, S. C. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691453 · Cited by 98
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R. N., Henriquez, K. M., Gassman, M., Cooper, K. M., Muller, D., Hetzel, S., Brown, R., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 88
Hallucinogen-persisting perception disorder
Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312451270 · Cited by 87
Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Further Studies in the Therapeutic Value of Lysergic Acid Diethylamide in Mental Illness
Sandison, R. A., & Whitelaw, J. D. A. (1957) · Journal of Mental Science · doi:10.1192/bjp.103.431.332 · Cited by 83
Persistent hallucinosis following repeated administration of hallucinogenic drugs.
ROSENTHAL, S. H. (1964) · American Journal of Psychiatry · doi:10.1176/ajp.121.3.238 · Cited by 82
Neuroimaging in moderate MDMA use: A systematic review
Müller, F., Lenz, C., Steiner, M. D., Dolder, P. C., Walter, M., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.12.010 · Cited by 81
Regulation of human research with LSD in the United States (1949-1987)
Bonson, K. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4777-4 · Cited by 74
Davis, A. K., Barsuglia, J. P., Windham-Herman, A.-M., Lynch, M., & Polanco, M. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2017.009 · Cited by 70
Self-citationPsychedelic use and intimate partner violence: The role of emotion regulation
Thiessen, M. S., Walsh, Z., Bird, B. M., & Lafrance, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118771782 · Cited by 60
Psychological Aspects of Cancer
Carr, B. I., & Steel, J. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4866-2 · Cited by 57
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2013) · Psychological Aspects of Cancer · doi:10.1007/978-1-4614-4866-2_17 · Cited by 53
Strassman, R. J. (1991) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1991.10472572 · Cited by 47
Psychedelic Drugs Reconsidered
W., D. M., Grinspoon, L., Bakalar, J. B., Winkelman, M., Andritzky, W., & Forte, R. (1999) · Journal for the Scientific Study of Religion · doi:10.2307/1387601 · Cited by 42
Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration
Oram, M. (2016) · History of Psychiatry · doi:10.1177/0957154x16648822 · Cited by 39
Davis, A. K., Renn, E., Windham-Herman, A.-M., Polanco, M., & Barsuglia, J. P. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1487607 · Cited by 37
Self-citationLSD in Psychotherapy and Alcoholism
Abramson, H. A. (1966) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1966.20.3.415 · Cited by 36
Mescaline: A Global History of the First Psychedelic
Jay, M. (2019) · Cited by 34
Long-term psychological effects of LSD.
McWilliams, S. A., & Tuttle, R. J. (1973) · Psychological Bulletin · doi:10.1037/h0034411 · Cited by 33
2018: A watershed year for psychedelic science
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2019) · Drug Science Policy and Law · doi:10.1177/2050324519872284 · Cited by 31
Self-citationNeural Mechanisms of Emotions and Affect
Aday, J. S., Rizer, W., & Carlson, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801851-4.00002-1 · Cited by 27
Self-citationCan Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Cognitive Enhancement · doi:10.1007/s41465-019-00151-6 · Cited by 27
Self-citationLong-term effects of depression treatment
Uher, R., & Pavlová, B. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00578-7 · Cited by 26
Placebo Problems: Boundary Work in the Psychedelic Science Renaissance
Hendy, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-76720-8_9 · Cited by 20
Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20thCentury
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1581961 · Cited by 20
Self-citationAixalà, M., Oña, G., Parés, Ò., & Bouso, J. C. (2019) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2019.1611739 · Cited by 18
Are psychedelics useful in the practice of Buddhism?
Stolaroff, M. J. (1999) · Journal of Humanistic Psychology · doi:10.1177/0022167899391009 · Cited by 17
The role of psychedelics in palliative care reconsidered: A case for psilocybin
Kelmendi, B., Corlett, P. R., Ranganathan, M., D’Souza, C., & Krystal, J. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675781 · Cited by 11
Garcia‐Romeu, A., Noorani, T. N., Griffiths, R. R., & Johnson, M. W. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.07.1130 · Cited by 5
Cited by
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
Self-citationDefault Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
“This review focuses on the classical psychedelics: LSD, psilocybin, DMT, mescaline, and ayahuasca (which contains DMT and harmala alkaloids), complementing previous reviews of these agents (Carhart-Harris and Friston, 2019; Aday et al., 2020; Inserra et al., 2021).”
BackgroundAday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Self-citationAday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224
Self-citationPeill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141
Metadata
- Authors
- Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 113
- Pages
- 179-189
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W3012354707
- Cited by
- 257
- References
- 121
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.